He has played key roles in the founding of Vical, Inc., a gene therapy company, Dynavax Technologies, a biopharmaceutical company, Triangle Pharmaceuticals, an anti-virus company; and Salmedix, an anti-cancer company. Dr. Carson is Director of Rebecca and John Moores UCSD Cancer Center and has been a Professor in the Department of Medicine at the University of California, San Diego since 1990. He was elected to the National Academy of Science in 2003.
Prior to joining UCSD, he was a member in the Department of Molecular and Experimental Medicine at The Scripps Research Institute. He received his B.A. from Haverford College and M.D. from Columbia University.
Gordon K. Davidson,
Ralph W. deVere
Dr. deVere White is president-elect of the Society of Urologic Oncology, the leading organization dedicated to developing new treatment strategies for urologic cancers. He is past chair of the U.S. Department of Defense Integrated Panel for Prostate Cancer Research, an advisory body that helps to administer federal grants for prostate cancer. He is also a past chair of the Southwest Oncology Group Applied Basic Research Committee and past president of the Urological Research Society.
Dr. deVere White has authored more than 200 peer-reviewed scientific articles and book chapters and edited three medical textbooks. He serves on the editorial boards of six international scientific journals.
With more than $2 million in research funding this year, Dr. deVere White is investigating the genetic mistakes that give rise to prostate cancer, the biomolecular mechanisms that make some prostate cancers more virulent than others, and new methods of diagnosing and treating prostate cancer. Over the past decade, he has been the principal investigator on research grants totaling nearly $6 million.
Among his many honors and awards, Dr. deVere White is a member of the Clinical Society of Genitourinary Surgeons. Surgeons are elected into this professional organization based on their outstanding contributions to urology. The highly selective society has only 25 members. Dr. deVere White is also an elected member of the prestigious American Association of Genitourinary Surgeons.
Dr. deVere White has been named multiple times as one of “The Best Doctors in America.” He is one of four urologists serving as a volunteer consultant to the American Cancer Society’s on-line “Experts Answers” bulletin board for questions about prostate cancer.
Dr. deVere White received his medical degree from Dublin University in Dublin, Ireland, and completed an internship and residencies in surgery and urology at St. Vincent’s Hospital in Dublin and at Duke University Medical Center in Durham, N.C.
John P. Fruehauf,
He earned a medical
degree and a doctorate degree in pharmacology from Rush University Medical
College in Chicago; he completed his residency at the University of California
at Irvine; he completed his oncology fellowship at the NCI.
Dr. Fruehauf researches mechanisms of drug action and resistance with the goal of developing predictive tests that improve therapeutic outcomes for cancer patients.
He has authored numerous book chapters, clinical articles, and abstracts, and has been published in peer-reviewed journals such as Gynecological Oncology, Clinical Cancer Research, American Journal of Clinical Pathology, and Cancer.
Judith C. Gasson,
In addition to her administrative duties, Gasson also is a gifted scientist. She was instrumental in purifying for the first time a hormone-like substance that increases the speed of bone marrow cell reproduction. That substance, called GM-CSF, is used to help prevent infections in cancer patients, and to allow patients to tolerate more chemotherapy and radiation than had previously been possible.
One of Gasson's continuing goals is to bring more of the fruits of basic research to patients' bedsides and under her leadership, the Jonsson Cancer Center has become known for its leading-edge translational research.
“Researchers here at UCLA's Jonsson Comprehensive Cancer Center have made tremendous headway in terms of cancer-related discoveries," Gasson said. “What we really need to do now is transfer those discoveries from the research laboratory to the hospital, where they will have impact on patient care: diagnosis, treatment and prevention.
“I want to bring the basic scientists, the physician researchers and the clinicians together to focus on specific types of cancer, and to take more basic scientific discoveries from the bench to the bedside.”
In 2005, Gasson was named a co-director of the UCLA Institute of Stem Cell Biology and Medicine and she recently testified before a key Senate subcommittee on the promise of stem cell research in cancer. Gasson also serves as a board member for the American Association for Cancer Research. She earned a doctorate in physiology at the University of Colorado in 1979, and did post doctoral work at the Salk Institute in La Jolla. In 1983, she left the Salk Institute to join UCLA's Jonsson Cancer Center.
“I came here because I wanted to do work on the cutting edge in a field where basic research can make an impact on patient care," Gasson said.
Jay T. Groves,
He has received many honors and awards, including the Merrill Lynch Innovation Grants Competitition Entrepreneurship Prize; Burroughs Wellcome Career Award in the Biomedical Sciences; Searle Scholars Award; MIT TR100; and the Beckman Young Investigator Award.
His research interests include physical chemistry of cell membranes and principles of molecular organization in cell membranes.